Blockbuster drugs and forecast accuracy: How sponsor type is associated with commercial success of FDA-approved medicines.

Authors

Michael R Myers, Michael Kinch, Kevin Murgas, Tyler Schwartz, Zachary Kraft, Andreas Dimakakos

Published in

Drug discovery today. Pages 104832. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

We evaluated the commercial performance of 490 FDA-approved new molecular entities (NMEs) and biologic products approved from 2016 through 2025 against analyst forecasts, testing the hypothesis that only a small proportion of approved drugs have the potential to generate substantial returns for their sponsors. We demonstrate that analyst forecasts are subject to considerable limitations, with systematic overestimation of sales particularly prevalent for drugs with biotech sponsors. We further identify a strong association with large, established pharmaceutical companies and their ability to select or develop commercially successful products relative to smaller competitors and emerging companies. Large pharma achieved blockbuster (BB) or super-blockbuster (SBB) status for approximately 34% of their approved portfolio, compared to approximately 9% for medium pharma and approximately 2% for biotech sponsors.

PMID:
42849831
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.